Prospective Clinical Trial of ¹⁸F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers.

ABSTRACT: ¹⁸F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (¹⁸F-fluciclovine) is a leucine analog radiotracer that depicts amino acid transport into cells. ¹⁸F-fluciclovine PET/CT visualizes malignancy, including prostate cancer, invasive ductal breast cancer, and invasive lobular breast cancer. Whether changes in ¹⁸F-fluciclovine avidity reflect changes in tumor burden resulting from treatment has not been shown. In this prospective clinical trial (clinical trials.gov: NCT01864083), changes in ¹⁸F-fluciclovine avidity after neoadjuvant therapy were compared to breast cancer therapy response, as determined by residual tumor burden on pathology, were evaluated. Methods: Twenty-four women with a new diagnosis of locally advanced in

SUBMITTER: Ulaner GA 

PROVIDER: S-EPMC6944156 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature